Stockscreener 앱 받기
4.04
0.00%
0.00
시간 외 거래:
4.05
0.010
+0.25%
전일 마감가:
$4.04
열려 있는:
$4.04
하루 거래량:
22,967
Relative Volume:
0.28
시가총액:
$37.41M
수익:
$4.01M
순이익/손실:
$-26.97M
주가수익비율:
-1.3599
EPS:
-2.9707
순현금흐름:
$-23.45M
1주 성능:
+0.00%
1개월 성능:
-4.94%
6개월 성능:
-50.12%
1년 성능:
-58.65%
1일 변동 폭
$4.02
$4.1628
1주일 범위
$3.82
$4.20
52주 변동 폭
$3.51
$13.13
Cervomed Inc Stock (CRVO) Company Profile
명칭
Cervomed Inc
전화
(617) 744-4400
주소
20 PARK PLAZA, BOSTON
Compare CRVO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
4.04 | 37.41M | 4.01M | -26.97M | -23.45M | -2.9707 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-13 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2024-12-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2024-12-06 | 개시 | ROTH MKM | Buy |
| 2024-12-05 | 개시 | H.C. Wainwright | Buy |
| 2024-09-18 | 개시 | Chardan Capital Markets | Buy |
| 2024-07-26 | 개시 | Morgan Stanley | Overweight |
| 2024-02-15 | 개시 | Canaccord Genuity | Buy |
| 2020-11-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | 개시 | H.C. Wainwright | Buy |
모두보기
Cervomed Inc 주식(CRVO)의 최신 뉴스
Operating cash flow per share of CervoMed Inc. – FWB:DP8 - TradingView — Track All Markets
CRVO Should I Buy - Intellectia AI
CRVO.O PE Ratio & Valuation, Is CRVO.O Overvalued - Intellectia AI
CRVO.O Forecast — Price Prediction for 2026. Should I Buy CRVO.O? - Intellectia AI
Buyout Rumor: Does CervoMed Inc have strong fundamentalsWeekly Stock Analysis & Verified Momentum Watchlists - baoquankhu1.vn
CRVO Stock Price, Quote & Chart | CERVOMED INC (NASDAQ:CRVO) - ChartMill
CRVO.O Technical Analysis & Stock Price Forecast - Intellectia AI
CRVO.O Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Lewy Body Dementia Market: Accelerating Growth And Pipeline Impact By 2034 Delveinsight Cognition Therapeutics, Keiferx, Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition Therapeutics - Mena FN
Lewy Body Dementia Market: Accelerating Growth and Pipeline - openPR.com
CervoMed Inc. prepares Phase 3 trial after CEO engages on advancing dementia biomarkers - Traders Union
CervoMed (CRVO) Maintains "Buy" Rating with $31 Price Target | C - GuruFocus
CervoMed Inc. Provides Neflamapimod Clinical Program Update and Announces Participation at 2026 Lewy Body Dementia Association Annual Meeting - Minichart
CervoMed Highlights Neflamapimod Progress in Lewy Body Dementia - TipRanks
AWM-owned funds hold 405,165 shares in CervoMed (CRVO) — 4.2% stake - Stock Titan
Form 8-KCurrent report - ADVFN
CervoMed Inc. Announces Neflamapimod Clinical Trial Updates and MRI Findings at Lewy Body Dementia Association Meeting - Quiver Quantitative
CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting - ChartMill
CRVO PE Ratio & Valuation, Is CRVO Overvalued - Intellectia AI
CRVO.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
CRVO News & Events - Intellectia AI
CervoMed sets 50mg dose for phase 3 dementia trial - Investing.com
CRVO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
CRVO Technical Analysis & Stock Price Forecast - Intellectia AI
Insider Buy: How do insiders feel about CervoMed IncPrice Action & Low Risk Profit Maximizing Plans - baoquankhu1.vn
CervoMed (CRVO)’s Q4 results feature advancements in its neflamapimod program for dementia Lewy bodies (DLB) - MSN
CervoMed (CRVO)’s Q4 Results Feature Advancements in Its Neflamapimod Program for Dementia Lewy Bodies (DLB) - Insider Monkey
CEO Change: Is CervoMed Inc stock overvalued or fairly priced2026 Technicals & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Top 5 Stocks Under $5 That Could Triple - insidermonkey.com
CervoMed Posts Investor Presentation Under Regulation FD Disclosure - TipRanks
CRVO: Phase III DLB trial launches this year, leveraging biomarker-driven selection and robust phase II data - TradingView
CervoMed (NASDAQ: CRVO) furnishes updated investor presentation via 8-K - Stock Titan
CervoMed Presents New Data Reinforcing Positive Effects of Tuvapimod in Dementia with Lewy Bodies Without Alzheimer’s Co-Pathology at AD/PD 2026 Conference - Minichart
CervoMed reports Phase 2b trial data for DLB treatment neflamapimod By Investing.com - in.investing.com
CervoMed Highlights RewinD-LB Phase 2b Biomarker-Driven Results - TipRanks
[8-K] CervoMed Inc. Reports Material Event - Stock Titan
CervoMed (CRVO): Analyst Maintains Buy Rating with $31 Price Tar - GuruFocus
CervoMed (CRVO) Showcases Promising Trial Results for Neflamapim - GuruFocus
CervoMed Inc Announces New Data on Neflamapimod In Dementia With Lewy Bodies - marketscreener.com
CervoMed reports Phase 2b trial data for DLB treatment neflamapimod - Investing.com
CervoMed Inc. unveils new analyses linking better neflamapimod outcomes to reduced Alzheimer co-pathology - Traders Union
CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology - The Manila Times
CervoMed Announces New Data at the AD/PD™ 2026 Scientific - GlobeNewswire
CRVO: Roth Capital Lowers Price Target, Maintains Buy Rating | C - GuruFocus
CervoMed (CRVO): Chardan Capital Raises Price Target to $21.00 | - GuruFocus
Market Trends: Is CervoMed Inc currently under institutional pressureDollar Strength & Smart Money Movement Tracker - baoquankhu1.vn
CervoMed Reports 2025 Results, Advances Neflamapimod Programs - TipRanks
CRVO: Phase 3 DLB trial planned for H2 2026, with cash runway limited to six months - TradingView
CervoMed (CRVO) widens 2025 loss as cash runway falls to six months - Stock Titan
Aug Macro: Is CervoMed Inc stock overvalued or fairly pricedWeekly Trading Summary & Real-Time Buy Zone Alerts - baoquankhu1.vn
H.C. Wainwright reiterates CervoMed stock rating on conference data By Investing.com - Investing.com India
Cervomed Inc (CRVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):